Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C17H20N2S |
| Molecular Weight | 284.419 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CN1C2=CC=CC=C2SC3=CC=CC=C13)N(C)C
InChI
InChIKey=PWWVAXIEGOYWEE-UHFFFAOYSA-N
InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3
| Molecular Formula | C17H20N2S |
| Molecular Weight | 284.419 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Promethazine is a phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. Promethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12657913 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
|||
| Primary | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
|||
| Primary | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
|||
| Preventing | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
|||
| Primary | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.75 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
25 mg single, rectal dose: 25 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9.04 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
19.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
11.28 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
21.84 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
48.26 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
10 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
12.5 mg single, intravenous dose: 12.5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
13.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
146 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
25 mg single, rectal dose: 25 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
256 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
361 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
146.62 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
180.14 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
627.13 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
14466 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
12.5 mg single, intravenous dose: 12.5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
11511 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
25 mg single, rectal dose: 25 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
17.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
18.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
12.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
12.5 mg single, intravenous dose: 12.5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1150 mg single, oral Overdose |
unhealthy, 14 |
Disc. AE: Sinus tachycardia, Consciousness decreased... AEs leading to discontinuation/dose reduction: Sinus tachycardia Sources: Consciousness decreased Agitation Confusion Disorientation Visual hallucinations Delirium |
160 mg single, intramuscular Highest studied dose Dose: 160 mg Route: intramuscular Route: single Dose: 160 mg Sources: |
healthy, 21.4±1.7 |
|
120 mg single, intramuscular Higher than recommended Dose: 120 mg Route: intramuscular Route: single Dose: 120 mg Sources: |
healthy, 22.7±2.31 |
|
80 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 80 mg, 1 times / day Route: intramuscular Route: multiple Dose: 80 mg, 1 times / day Sources: |
healthy, 24.2±1.17 |
|
50 mg single, intramuscular|intravenous Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Respiratory depression, Irritation skin... AEs leading to discontinuation/dose reduction: Respiratory depression (grade 5) Sources: Irritation skin (severe) Pain Thrombophlebitis |
50 mg single, oral Recommended Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Respiratory depression... AEs leading to discontinuation/dose reduction: Respiratory depression (grade 5) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Agitation | Disc. AE | 1150 mg single, oral Overdose |
unhealthy, 14 |
| Confusion | Disc. AE | 1150 mg single, oral Overdose |
unhealthy, 14 |
| Consciousness decreased | Disc. AE | 1150 mg single, oral Overdose |
unhealthy, 14 |
| Delirium | Disc. AE | 1150 mg single, oral Overdose |
unhealthy, 14 |
| Disorientation | Disc. AE | 1150 mg single, oral Overdose |
unhealthy, 14 |
| Sinus tachycardia | Disc. AE | 1150 mg single, oral Overdose |
unhealthy, 14 |
| Visual hallucinations | Disc. AE | 1150 mg single, oral Overdose |
unhealthy, 14 |
| Pain | Disc. AE | 50 mg single, intramuscular|intravenous Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
| Thrombophlebitis | Disc. AE | 50 mg single, intramuscular|intravenous Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
| Respiratory depression | grade 5 Disc. AE |
50 mg single, intramuscular|intravenous Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
| Irritation skin | severe Disc. AE |
50 mg single, intramuscular|intravenous Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
| Respiratory depression | grade 5 Disc. AE |
50 mg single, oral Recommended Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes [IC50 32 uM] | ||||
| yes [Inhibition 88 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes | ||||
| yes |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Hyperalgesia induced by Asp49 and Lys49 phospholipases A2 from Bothrops asper snake venom: pharmacological mediation and molecular determinants. | 2003-05 |
|
| The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers. | 2003-04 |
|
| Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view. | 2003-04 |
|
| Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. | 2003-04 |
|
| Clinical practice. Vestibular neuritis. | 2003-03-13 |
|
| Phenothiazine radicals inactivate Trypanosoma cruzi dihydrolipoamide dehydrogenase: enzyme protection by radical scavengers. | 2003-03 |
|
| Effect of some psychotropic drugs on luminol-dependent chemiluminescence induced by O2-, *OH, HOCl. | 2003-02-04 |
|
| Inactivation of cholinesterase induced by chlorpromazine cation radicals. | 2003-02 |
|
| Effect of phenothiazines on protein kinase C- and calcium-dependent activation of peritoneal macrophages. | 2003-02 |
|
| Interaction between various resistance modifiers and apoptosis inducer 12H-benzo[alpha]phenothiazine. | 2003-01-18 |
|
| Reye's syndrome: down but not out. | 2003-01 |
|
| Interaction of carbamazepine and promethazine in rabbits. | 2003-01 |
|
| In vitro human plasma leucine(5)-enkephalin degradation is inhibited by a select number of drugs with the phenothiazine molecule in their chemical structure. | 2003-01 |
|
| Antiemetic use in pediatric gastroenteritis: a national survey of emergency physicians, pediatricians, and pediatric emergency physicians. | 2002-12-05 |
|
| A systematic approach to the management of postoperative nausea and vomiting. | 2002-12 |
|
| Fibromyositis after intramuscular pentazocine abuse. | 2002-11-15 |
|
| TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms [ISRCTN44153243]. | 2002-10-16 |
|
| Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. | 2002-10 |
|
| Preparation, characterization and taste-masking properties of polyvinylacetal diethylaminoacetate microspheres containing trimebutine. | 2002-10 |
|
| Acute allergic reaction following contact with a spider. | 2002-10 |
|
| Enantioseparation of phenothiazines in cyclodextrin-modified micellar electrokinetic chromatography. | 2002-09-20 |
|
| Project USAP 2000--use of sedative agents by pediatric dentists: a 15-year follow-up survey. | 2002-09-06 |
|
| [Landau-Kleffner and autistic regression: the importance of differential diagnosis]. | 2002-09 |
|
| A case of homicide by lethal injection with lidocaine. | 2002-09 |
|
| Recovery, enrichment and selectivity in liquid-phase microextraction comparison with conventional liquid-liquid extraction. | 2002-07-19 |
|
| Bradykinin is involved in hyperalgesia induced by Bothrops jararaca venom. | 2002-07 |
|
| Simultaneous determination of promethazine, chlorpromazine, and perphenazine by multivariate calibration methods and derivative spectrophotometry. | 2002-06-27 |
|
| Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. | 2002-06-19 |
|
| In vitro reversal of chloroquine resistance in Plasmodium falciparum with dihydroethanoanthracene derivatives. | 2002-06 |
|
| Indirect spectrophotometric determination of propranolol hydrochloride and piroxicam in pure and pharmaceutical formulations. | 2002-06 |
|
| Central effects of cinnarizine: restricted use in aircrew. | 2002-06 |
|
| Next generation antihistamines: therapeutic rationale, accomplishments and advances. | 2002-06 |
|
| Investigation of interaction of promethazine with cyclodextrins. | 2002-05-25 |
|
| Interaction of protonated anticancer thiazines with water-insoluble phospholipids and antineoplastic agents. | 2002-05-17 |
|
| Liquid-phase microextraction of protein-bound drugs under non-equilibrium conditions. | 2002-05 |
|
| Anxiolytic premedication reduces preoperative anxiety and pain during oocyte retrieval. A randomized double-blinded placebo-controlled trial. | 2002-05 |
|
| Study of the stability of promethazine enantiomers by liquid chromatography using a vancomycin-bonded chiral stationary phase. | 2002-04-25 |
|
| Investigation of the effect of tablet surface area/volume on drug release from hydroxypropylmethylcellulose controlled-release matrix tablets. | 2002-04 |
|
| Immunoassay screening of lysergic acid diethylamide (LSD) and its confirmation by HPLC and fluorescence detection following LSD ImmunElute extraction. | 2002-04 |
|
| [Validation of the HPLC method in the determination of dioxopromethazine and phenylephrine in eye drops]. | 2002-03 |
|
| Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes. | 2002-02 |
|
| An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. | 2002-01 |
|
| [A case of fluvoxamine overdose]. | 2002-01 |
|
| [The activity of enzymes and free radical oxidation in acute and chronic fetal hypoxia in general anesthesia during cesarean section]. | 2002 |
|
| Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity. | 2002 |
|
| [Suicidal attempts with old (currently unused) drug]. | 2002 |
|
| Antiallergic anti-inflammatory effects of H1-antihistamines in humans. | 2002 |
|
| Antihistamine antinociception is mediated by Gi-protein activation. | 2002 |
|
| [Work time distribution in night shift: are clinics facing a adjustment boom?]. | 2001-07 |
|
| The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. | 2001 |
Sample Use Guides
Allergy: the average oral dose is 25 mg taken before retiring; however, 12.5 mg may be taken before meals and on retiring, if necessary. Single 25 mg doses at bedtime or 6.25 to 12.5 mg taken three times daily will usually suffice. After initiation of treatment in children or adults, dosage should be adjusted to the smallest amount adequate to relieve symptoms. The administration of promethazine HCI in 25 mg doses will control minor transfusion reactions of an allergic nature.
Motion Sickness: the average adult dose is 25 mg taken twice daily. The initial dose should be taken one-half to one hour before anticipated travel and be repeated 8 to 12 hours later, if necessary. On succeeding days of travel, it is recommended that 25 mg be taken on arising and again before the evening meal. For children, 12.5 to 25 mg, twice daily, may be administered.
Nausea and Vomiting: antiemetics should not be used in vomiting of unknown etiology in children and adolescents. The average effective dose of Promethazine HCL Oral Solution for the active therapy of nausea and vomiting in children or adults is 25 mg. When oral medication cannot be tolerated, the dose should be given parenterally or by rectal suppository. 12.5 to 25 mg doses may be repeated, as necessary, at 4 to 6 hour intervals. For nausea and vomiting in children, the usual dose is 0.5 mg per pound of body weight, and the dose should be adjusted to the age and weight of the patient and the severity of the condition being treated.
For prophylaxis of nausea and vomiting, as during surgery and the postoperative period, the average dose is 25 mg repeated at 4 to 6 hour intervals, as necessary.
Sedation: this product relieves apprehension and induces a quiet sleep from which the patient can be easily aroused. Administration of 12.5 to 25 mg Promethazine HCl Oral Solution by the oral route will provide sedation in children. Adults usually require 25 to 50 mg for nighttime, presurgical, or obstetrical sedation.
Pre- and Postoperative Use: promethazine HCl Oral Solution in 12.5 to 25 mg doses for children and 50 mg doses for adults the night before surgery relieves apprehension and produces a quiet sleep.
For preoperative medication, children require doses of 0.5 mg per pound of body weight in combination with an appropriately reduced dose of narcotic or barbiturate and the appropriate dose of an atropine-like drug.
Usual adult dosage is 50 mg Promethazine HCl Oral Solution with an appropriately reduced dose of narcotic or barbiturate and the required amount of a belladonna alkaloid. Postoperative sedation and adjunctive use with analgesics may be obtained by the administration of 12.5 to 25 mg in children and 25 to 50 mg doses in adults. Promethazine HCL Oral Solution is contraindicated for children under 2 years of age.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:58:15 GMT 2025
by
admin
on
Mon Mar 31 17:58:15 GMT 2025
|
| Record UNII |
FF28EJQ494
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QR06AD52
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
||
|
WHO-ATC |
V03AB05
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
||
|
WHO-ATC |
R06AD52
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
||
|
NCI_THESAURUS |
C740
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
||
|
NDF-RT |
N0000007544
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
||
|
NDF-RT |
N0000175746
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
||
|
NDF-RT |
N0000007544
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
||
|
LIVERTOX |
NBK548427
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
||
|
WHO-VATC |
QD04AA10
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
||
|
NDF-RT |
N0000007544
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
||
|
WHO-ATC |
D04AA10
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
||
|
WHO-VATC |
QR06AD02
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
||
|
WHO-ATC |
R06AD02
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
||
|
WHO-VATC |
QV03AB05
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
73745-50-3
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
SUPERSEDED | |||
|
DB01069
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
PROMETHAZINE
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
m9171
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | Merck Index | ||
|
200-489-2
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
DTXSID7023518
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
SUB10088MIG
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
C779
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
60-87-7
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
8461
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
2286
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
30321
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
3173
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
100000081146
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
516
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
7282
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
CHEMBL643
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
FF28EJQ494
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
D011398
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
8745
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | RxNorm | ||
|
4927
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
FF28EJQ494
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY | |||
|
Promethazine
Created by
admin on Mon Mar 31 17:58:15 GMT 2025 , Edited by admin on Mon Mar 31 17:58:15 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
METABOLIC ENZYME -> INHIBITOR |
Ki
|
||
|
ENANTIOMER -> RACEMATE | |||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
METABOLITE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| LIVER/PLASMA RATIO | PHARMACOKINETIC |
|
||||
| Volume of Distribution | PHARMACOKINETIC |
|
|
|||
| Biological Half-life | PHARMACOKINETIC |
|
Elimination PHARMACOKINETIC PHARMACOKINETIC PHARMACOKINETIC PHARMACOKINETIC |
|
||
| LIVER CONCENTRATION | PHARMACOKINETIC |
|
||||